Tekmira Pharmaceuticals acquires worldwide license to novel RNAi Technology Tekmira Pharmaceuticals announced that it has obtained a worldwide, non-exclusive license to a novel RNAi payload technology called Unlocked Nucleobase Analog, or UNA, from Marina Biotech, for the development of RNAi therapeutics. UNA technology can be used in the development of RNAi therapeutics, which treat disease by silencing specific disease causing genes. UNAs can be incorporated into RNAi drugs and have the potential to improve them by increasing their stability and reducing off-target effects.
News For TKMR From The Last 14 Days
Check below for free stories on TKMR the last two weeks.